AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34332332 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional abuse
Number of subjects: 147
Study 34332332 — intervention group
Group type: EXPERIMENTAL
Intervention: Final models
Number of subjects: 147
Study 35381164 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan, Melphalan, and Etoposide (BuME)
Number of subjects: 75
Study 35381164 — intervention group
Group type: COMPARATOR
Intervention: Busulfan, Cyclophosphamide, and Etoposide (BuCE)
Number of subjects: 75
Study 33515972 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth choice decision aid booklet
Number of subjects: 65
Study 33515972 — intervention group
Group type: COMPARATOR
Intervention: Usual care (general maternal health booklet)
Number of subjects: 65
Study 35909585 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional breathing therapy (TG)
Number of subjects: 40
Study 32720582 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity statin, ezetimibe, and high-dose proprotein convertase subtilisin/kexin type 9 inhibitor
Number of subjects: 22
Study 32720582 — intervention group
Group type: COMPARATOR
Intervention: New time-dependent model
Number of subjects: 22
Study 35082351 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical-possession condition (participants possessed a tangible placebo analgesic oil)
Number of subjects: 90
Study 35082351 — intervention group
Group type: COMPARATOR
Intervention: Psychological-possession condition (participants possessed a coupon for a placebo analgesic oil)
Number of subjects: 90
Study 35082351 — intervention group
Group type: COMPARATOR
Intervention: No-possession condition
Number of subjects: 90
Study 33878835 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified posteromedial approach via lateral side of flexor hallucis longus
Number of subjects: 43
Study 33878835 — intervention group
Group type: COMPARATOR
Intervention: Modified posteromedial approach
Number of subjects: 43
Study 35452261 — intervention group
Group type: EXPERIMENTAL
Intervention: Language intervention with a peer with typically developing language (TDL)
Number of subjects: 20
Study 35452261 — intervention group
Group type: COMPARATOR
Intervention: Language intervention with a peer with developmental language disorder (DLD)
Number of subjects: 20
Study 33548329 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.5 mg dexamethasone and 800 mg ibuprofen
Number of subjects: 94
Study 33548329 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg dexamethasone
Number of subjects: 94
Study 33548329 — intervention group
Group type: COMPARATOR
Intervention: 800 mg ibuprofen
Number of subjects: 94
Study 33548329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 33164611 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 7.5 mg daily
Number of subjects: 138
Study 33164611 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg daily
Number of subjects: 138
Study 33164611 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg daily
Number of subjects: 138
Study 33164611 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate 7.5 mg/week (titrated to ≤15 mg/week)
Number of subjects: 138
Study 33381165 — intervention group
Group type: EXPERIMENTAL
Intervention: taVNS
Number of subjects: 30
Study 33381165 — intervention group
Group type: COMPARATOR
Intervention: staVNS
Number of subjects: 30
Study 36148320 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 μg/(kg·min) mivacurium (group M1)
Number of subjects: 99
Study 36148320 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 μg/(kg·min) mivacurium (group M2)
Number of subjects: 99
Study 36148320 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 μg/(kg·min) mivacurium (group M3)
Number of subjects: 99
Study 33668062 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 100% of the choline AI
Number of subjects: 0
Study 33668062 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 50% of the choline AI
Number of subjects: 0
Study 33668062 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 25% of the choline AI
Number of subjects: 0
Study 33668062 — intervention group
Group type: EXPERIMENTAL
Intervention: MRS analysis
Number of subjects: 0
Study 33668062 — intervention group
Group type: EXPERIMENTAL
Intervention: MS analysis of plasma
Number of subjects: 0
Study 33668062 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma betaine concentrations
Number of subjects: 0
Study 32381105 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation educational intervention
Number of subjects: 0
Study 32381105 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital didactic environment educational intervention
Number of subjects: 0
Study 32381105 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33992088 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for GPs
Number of subjects: 833
Study 33992088 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 833
Study 32609847 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-E (cutting-out the easiest cigarettes first)
Number of subjects: 342
Study 32609847 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-D (cutting-out the most difficult cigarettes first)
Number of subjects: 342
Study 32609847 — intervention group
Group type: EXPERIMENTAL
Intervention: SFP (not smoking during particular periods)
Number of subjects: 342
Study 32609847 — intervention group
Group type: EXPERIMENTAL
Intervention: SR (smoking on an increasing time schedule)
Number of subjects: 342
Study 32609847 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual cessation methods (overall)
Number of subjects: 342
Study 35904950 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy followed by laser therapy (980 nm DL, 1 W, continuous wave mode, 20 sec per tooth side, repeated twice at 5‐7 day intervals)
Number of subjects: 36
Study 35904950 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical periodontal therapy
Number of subjects: 36
Study 35904950 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy followed by laser therapy
Number of subjects: 36
Study 32412917 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription Tongxin
Number of subjects: 48
Study 32412917 — intervention group
Group type: COMPARATOR
Intervention: Shexiang Baoxin Pill
Number of subjects: 48
Study 32484850 — intervention group
Group type: EXPERIMENTAL
Intervention: SENATOR software-guided medication optimization plus standard care
Number of subjects: 1537
Study 32484850 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 1537
Study 35638918 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 190
Study 35638918 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 190
Study 33542551 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial cystectomy and adjunctive medical therapy (Group A)
Number of subjects: 47
Study 33542551 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone (Group B)
Number of subjects: 47
Study 32074624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT) + Treatment as Usual (TAU)
Number of subjects: 132
Study 32074624 — intervention group
Group type: COMPARATOR
Intervention: Specialized Attention Therapy (SAT) + Treatment as Usual (TAU)
Number of subjects: 132
Study 35651925 — intervention group
Group type: EXPERIMENTAL
Intervention: AI limb rehabilitation system on account of VR technology
Number of subjects: 50
Study 35651925 — intervention group
Group type: COMPARATOR
Intervention: Traditional drug therapy
Number of subjects: 50
Study 33707105 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light blocking (BLB) glasses
Number of subjects: 20
Study 33707105 — intervention group
Group type: COMPARATOR
Intervention: Control (clear lens) glasses
Number of subjects: 20
Study 32379974 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF) model for predicting relative response factors (RRFs) using CE-MS ESI+ data set
Number of subjects: 0
Study 32379974 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF) model for predicting RRFs using LC-QTOF/MS ESI+ data set
Number of subjects: 0
Study 32379974 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF) model for predicting RRFs using LC-QTOF/MS ESI- data set
Number of subjects: 0
Study 32379974 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) model for predicting RRFs; specific outcomes not detailed in the abstract
Number of subjects: 0
Study 33620614 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessed with WHOQOL-BREF (psychological domain)
Number of subjects: 479
Study 33620614 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessed with WHOQOL-BREF (social relationships domain)
Number of subjects: 479
Study 33620614 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessed with WHOQOL-BREF (physical health domain)
Number of subjects: 479
Study 33620614 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessed with WHOQOL-BREF (environment domain)
Number of subjects: 479
Study 32222613 — intervention group
Group type: COMPARATOR
Intervention: Excluded participants
Number of subjects: 130
Study 32222613 — intervention group
Group type: EXPERIMENTAL
Intervention: Included participants
Number of subjects: 130
Study 36345922 — intervention group
Group type: EXPERIMENTAL
Intervention: Durapore (DP)
Number of subjects: 112
Study 36345922 — intervention group
Group type: COMPARATOR
Intervention: Hy-Tape (HT)
Number of subjects: 112
Study 32032096 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalogram-guided anesthesia
Number of subjects: 1113
Study 32032096 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1113
Study 32032096 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalogram suppression
Number of subjects: 1113
Study 32032096 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative abnormal cognition
Number of subjects: 1113
Study 33883615 — intervention group
Group type: EXPERIMENTAL
Intervention: Aptamer Apt1
Number of subjects: 0
Study 33883615 — intervention group
Group type: EXPERIMENTAL
Intervention: Aptamer Apt2
Number of subjects: 0
Study 36232045 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 12
Study 36232045 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 12
Study 33799119 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality warm-up before surgery
Number of subjects: 34
Study 33799119 — intervention group
Group type: EXPERIMENTAL
Intervention: Running Suture task on the simulator
Number of subjects: 34
Study 33799119 — intervention group
Group type: COMPARATOR
Intervention: Control group (no warm-up)
Number of subjects: 34
Study 32336153 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet adherence (highest quartile)
Number of subjects: 1050
Study 32336153 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet adherence (highest quartile) in postmenopausal women
Number of subjects: 1050
Study 32336153 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet adherence (highest quartile) in premenopausal women
Number of subjects: 1050
Study 32336153 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet adherence (highest quartile) among normal-weight women
Number of subjects: 1050
Study 32336153 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet adherence (highest quartile) among obese women
Number of subjects: 1050
Study 35987093 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Behavioral Intervention for Tics (CBIT)
Number of subjects: 32
Study 35987093 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 32
Study 35987093 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG coherence during a Go/NoGo task
Number of subjects: 32
Study 33794122 — intervention group
Group type: COMPARATOR
Intervention: Surrogates of patients living at home
Number of subjects: 256
Study 33794122 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogates of patients readmitted to an acute care hospital
Number of subjects: 256
Study 33794122 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogates of patients who died
Number of subjects: 256
Study 32940615 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided, internet-delivered psychological intervention (9-step program focusing on stress, worry, and valued action)
Number of subjects: 7
Study 36082508 — intervention group
Group type: EXPERIMENTAL
Intervention: NRPT 1X (recommended daily dose)
Number of subjects: 111
Study 36082508 — intervention group
Group type: EXPERIMENTAL
Intervention: NRPT 2X (double dose)
Number of subjects: 111
Study 36082508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 34087229 — intervention group
Group type: EXPERIMENTAL
Intervention: VM hysteropexy
Number of subjects: 94
Study 34087229 — intervention group
Group type: EXPERIMENTAL
Intervention: Native tissue repair
Number of subjects: 94
Study 34087229 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 94
Study 35410939 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive behavioural therapy (iCBT)
Number of subjects: 0
Study 35410939 — intervention group
Group type: COMPARATOR
Intervention: online discussion forum (ODF)
Number of subjects: 0
Study 34111898 — intervention group
Group type: EXPERIMENTAL
Intervention: Humanoid Robot
Number of subjects: 117
Study 34111898 — intervention group
Group type: COMPARATOR
Intervention: Tablet Computer
Number of subjects: 117
Study 34111898 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Robot and Tablet
Number of subjects: 117
Study 36372250 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified EPA (1800 mg/day)
Number of subjects: 2460
Study 36372250 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2460
Study 36372250 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational part
Number of subjects: 2460
Study 32912416 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined catheterization group (TEG + POCUS)
Number of subjects: 97
Study 32912416 — intervention group
Group type: COMPARATOR
Intervention: Routine catheterization group
Number of subjects: 97
Study 36343427 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1358894 (100 mg)
Number of subjects: 73
Study 36343427 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (20 mg)
Number of subjects: 73
Study 36343427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 34134450 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/day
Number of subjects: 46
Study 34134450 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day
Number of subjects: 46
Study 34134450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 33054248 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy diet
Number of subjects: 120
Study 33054248 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium energy diet
Number of subjects: 120
Study 33054248 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy diet
Number of subjects: 120
Study 35315257 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaxerenone 5-mg orally disintegrating tablet (ODT) taken with water
Number of subjects: 0
Study 35315257 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaxerenone 5-mg orally disintegrating tablet (ODT) taken without water
Number of subjects: 0
Study 35315257 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral tablet (5-mg)
Number of subjects: 0
Study 32251766 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative/low regulation temperament group
Number of subjects: 660
Study 32251766 — intervention group
Group type: COMPARATOR
Intervention: Neutral/average regulation temperament group
Number of subjects: 660
Study 32251766 — intervention group
Group type: COMPARATOR
Intervention: Positive/high regulation temperament group
Number of subjects: 660
Study 32251766 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall dietary behavior
Number of subjects: 660
Study 32251766 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperament interaction with intervention
Number of subjects: 660
Study 36328115 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1859
Study 36328115 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1859
Study 33180929 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi‐tetanus toxoid conjugate (Vi‐TT) vaccine
Number of subjects: 0
Study 33180929 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi‐polysaccharide (Vi‐PS) vaccine
Number of subjects: 0
Study 33180929 — intervention group
Group type: COMPARATOR
Intervention: Vi‐TT and Vi‐PS vaccines (combined analysis)
Number of subjects: 0
Study 32482617 — intervention group
Group type: EXPERIMENTAL
Intervention: Firehawk stent
Number of subjects: 1653
Study 32482617 — intervention group
Group type: COMPARATOR
Intervention: XIENCE stent
Number of subjects: 1653
Study 34506037 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic closed-incision negative pressure wound therapy dressing
Number of subjects: 1459
Study 34506037 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ?40 kg/m2
Number of subjects: 1459
Study 34506037 — intervention group
Group type: EXPERIMENTAL
Intervention: ?2 previous pregnancies
Number of subjects: 1459
Study 34506037 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-CS vaginal cleansing
Number of subjects: 1459
Study 34565428 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular endoscopies
Number of subjects: 100
Study 34565428 — intervention group
Group type: COMPARATOR
Intervention: Endoscopies at need
Number of subjects: 100
Study 34565428 — intervention group
Group type: COMPARATOR
Intervention: NHS Digital data
Number of subjects: 100
Study 34565428 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial-specific data
Number of subjects: 100
Study 32059120 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate coronary angiogram (CAG)
Number of subjects: 970
Study 32059120 — intervention group
Group type: COMPARATOR
Intervention: Delayed coronary angiogram (CAG)
Number of subjects: 970
Study 35489376 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine (5 µg SARS-CoV-2 recombinant spike protein with 50 µg Matrix-M adjuvant)
Number of subjects: 4408
Study 35489376 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine
Number of subjects: 4408
Study 35489376 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 4408
Study 33517233 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine cigarettes (various contents: 1.3, 2.3, 5.5, 11.2, and 17.4 mg/g)
Number of subjects: 37
Study 33517233 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol cigarettes (matched on nicotine)
Number of subjects: 37
Study 33517233 — intervention group
Group type: COMPARATOR
Intervention: Very Low Nicotine Content (VLNC) cigarettes (0.4 mg/g)
Number of subjects: 37
Study 34255679 — intervention group
Group type: EXPERIMENTAL
Intervention: MY-RID intervention (smartphone-based messages delivered over 6 weeks)
Number of subjects: 97
Study 34255679 — intervention group
Group type: EXPERIMENTAL
Intervention: MY-RID intervention
Number of subjects: 97
Study 34255679 — intervention group
Group type: COMPARATOR
Intervention: Control group (attention control)
Number of subjects: 97
Study 35388471 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir (300/100 mg b.i.d.)
Number of subjects: 0
Study 35388471 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir (5-day regimen)
Number of subjects: 0
Study 35388471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33534381 — intervention group
Group type: EXPERIMENTAL
Intervention: OS eyes with glaucoma (OSWG)
Number of subjects: 26
Study 33534381 — intervention group
Group type: EXPERIMENTAL
Intervention: OS eyes without glaucoma (OSWOG)
Number of subjects: 26
Study 33534381 — intervention group
Group type: COMPARATOR
Intervention: Healthy control eyes
Number of subjects: 26
Study 33293038 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-Ketamine (P-K)
Number of subjects: 120
Study 33293038 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine-Ketamine (D-K)
Number of subjects: 120
Study 33293038 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 34530127 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive distal pancreatectomy (MIDP)
Number of subjects: 108
Study 34530127 — intervention group
Group type: COMPARATOR
Intervention: Open distal pancreatectomy (ODP)
Number of subjects: 108
Study 35940567 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC plus HCQ
Number of subjects: 926
Study 35940567 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC plus HCQ placebo
Number of subjects: 926
Study 35940567 — intervention group
Group type: EXPERIMENTAL
Intervention: HCQ plus TDF/FTC placebo
Number of subjects: 926
Study 35940567 — intervention group
Group type: COMPARATOR
Intervention: TDF/FTC placebo plus HCQ placebo
Number of subjects: 926
Study 35940567 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 926
Study 33651018 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical revision of secondary labial deformities
Number of subjects: 21
Study 32554835 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Persian medicine (TPM) strategies including exercise, nutrition, massage, bathing, aromatherapy, and sleeping.
Number of subjects: 0
Study 34844107 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 58
Study 34844107 — intervention group
Group type: COMPARATOR
Intervention: Insulin (INS)
Number of subjects: 58
Study 33931371 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa trigger followed by a bolus of 1500 IU HCG s.c. on the oocyte retrieval day and 1000 IU HCG s.c. 4 days later, no vaginal LPS (Group A)
Number of subjects: 250
Study 33931371 — intervention group
Group type: COMPARATOR
Intervention: 6500 IU HCG trigger followed by a standard vaginal progesterone LPS (Group B)
Number of subjects: 250